FDA MAY PROVIDE ASSISTANCE TO HCFA IN MAKING MEDICARE DEVICE COVERAGE DECISIONS; FDA EVALUATING HCFA HOME-USE DEVICE DATA FOR DESIGNING CLINICAL STUDIES
This article was originally published in The Gray Sheet
Executive Summary
An FDA role in device Medicare coverage decisions made by the Health Care Financing Administration is being explored by the two agencies. FDA's Center for Devices and Radiological Health and HCFA's Bureau of Policy & Development have held preliminary talks over the past several weeks to discuss ways in which device data received by CDRH might be helpful to HCFA in making coverage decisions.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.